+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 13Years - 17Years
All Genders
ID07288567

Evaluating KarXT Versus Placebo for Treating Schizophrenia in Adolescents Aged 13 to 17 Years

Led by Bristol-Myers Squibb · Updated on 2026-10-06

166

Participants Needed

37

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating KarXT for the treatment of schizophrenia in adolescents aged 13 to 17 years. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of KarXT in this population experiencing active symptoms of psychosis. The study is sponsored by Bristol-Myers Squibb and focuses on improving schizophrenia symptoms as measured by standard clinical scales. Participants will be randomly assigned to receive either KarXT or a matching placebo with specified doses on designated days. The study uses a parallel design with quadruple masking to compare outcomes between the two groups. The primary treatment phase lasts 5 weeks, during which the effects of KarXT on schizophrenia symptoms will be closely monitored. During the study, participants will undergo assessments including the Positive and Negative Syndrome Scale PANSS, Clinical Global Impression-Severity CGI-S, and Childrens Global Assessment Scale CGAS at baseline and Week 5. These measures track changes in symptom severity and overall functioning. Safety and tolerability will also be evaluated throughout the trial, which is expected to complete by December 2029.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here